Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure
Open Access
- 10 February 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
Abstract
Heart failure (HF) is a common complication or late-stage manifestation of various heart diseases. Numerous risk factors and underlying causes may contribute to the occurrence and progression of HF. The pathophysiological mechanisms of HF are very complicated. Despite accumulating advances in treatment for HF during recent decades, it remains an intractable clinical syndrome with poor outcomes, significantly reducing the quality of life and expectancy of patients, and imposing a heavy economic burden on society and families. Although initially classified as antidiabetic agents, sodium-glucose co-transporter 2 (SGLT2) inhibitors have demonstrated reduced the prevalence of hospitalization for HF, cardiovascular death, and all-cause death in several large-scale randomized controlled clinical trials. These beneficial effects of SGLT-2 inhibitors can be attributed to multiple hemodynamic, inflammatory and metabolic mechanisms, not only reducing the serum glucose level. SGLT2 inhibitors have been used increasingly in treatment for patients with HF with reduced ejection fraction due to their surprising performance in improving the prognosis. In addition, their roles and mechanisms in patients with HF with preserved ejection fraction or acute HF have also attracted attention. In this review article, we discuss the possible mechanisms and applications of SGLT2 inhibitors in HF.Keywords
This publication has 142 references indexed in Scilit:
- Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic miceEuropean Journal of Pharmacology, 2013
- Insulin Resistance and Heart Failure: Molecular MechanismsHeart Failure Clinics, 2012
- Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on MetforminJournal of Clinical Endocrinology & Metabolism, 2012
- Diabetes and the Risk of Heart FailureHeart Failure Clinics, 2012
- Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic ratAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2012
- Oxidative stress and heart failureAmerican Journal of Physiology-Heart and Circulatory Physiology, 2011
- Biology of Human Sodium Glucose TransportersPhysiological Reviews, 2011
- Diabetes, Glycemic Control, and New-Onset Heart Failure in Patients With Stable Coronary Artery DiseaseDiabetes Care, 2010
- The Impact of Obesity on the Left Ventricle: The Multi-Ethnic Study of Atherosclerosis (MESA)JACC: Cardiovascular Imaging, 2010
- AGE/RAGE produces endothelial dysfunction in coronary arterioles in Type 2 diabetic miceAmerican Journal of Physiology-Heart and Circulatory Physiology, 2008